Alora Pharmaceuticals

Alora Pharmaceuticals General Information

Alora Pharmaceuticals operates a broad commercial portfolio with more than forty branded and generic pharmaceutical products. Its lead programs include transdermal estradiol therapy for menopausal symptoms/prevention of osteoporosis ("Alora"), ADHD medication ("Relexxii®"), hypothyroidism treatment ("NP Thyroid®" via Acella), among others. Clinical results for its flagship product "Alora" show statistically significant improvement over placebo in bone mineral density after two years of use for postmenopausal osteoporosis prevention.[6] The company continues to expand its offerings through acquisitions and partnerships. Pipeline_breadth estimates at least forty commercialized or late-stage programs/products across multiple subsidiaries.[8]

Contact Information